ArticleThe American journal of pathology1995
Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a new animal model.
Article in The American journal of pathology, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 107 citations in OpenAlex.
- Article
- Immune responses and therapeutic options in psoriasis.Cellular and molecular life sciences : CMLS · 2021Review
- Contribution ofMediators of inflammation · 2017Review
- Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis--xenograft model.Journal of autoimmunity · 2014Article
- Crosstalk between keratinocytes and T cells in a 3D microenvironment: a model to study inflammatory skin diseases.The Journal of investigative dermatology · 2014Article
- Development of a bioengineered skin-humanized mouse model for psoriasis: dissecting epidermal-lymphocyte interacting pathways.The American journal of pathology · 2010Article
- Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.British journal of pharmacology · 2010Article
- Post-genomics and skin inflammation.Mediators of inflammation · 2010Review
- [Psoriasis SCID-mouse model].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2006Review
- Amphiregulin and epidermal hyperplasia: amphiregulin is required to maintain the psoriatic phenotype of human skin grafts on severe combined immunodeficient mice.The American journal of pathology · 2005Article
- Psoriasis treatment: current and emerging directed therapies.Annals of the rheumatic diseases · 2005Review
- A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice.The American journal of pathology · 2005Article
- Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model.The Journal of clinical investigation · 2003Article
- Proteasome inhibition: a new anti-inflammatory strategy.Journal of molecular medicine (Berlin, Germany) · 2003Review
- Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation.Nature medicine · 2002Article
- Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis.The American journal of pathology · 1999Article
- Tuberculin-induced delayed-type hypersensitivity reaction in a model of hu-PBMC-SCID mice grafted with autologous skin.The American journal of pathology · 1998Article
- Giant cell vasculitis is a T cell-dependent disease.Molecular medicine (Cambridge, Mass.) · 1997Article
- Dermal injection of immunocytes induces psoriasis.The Journal of clinical investigation · 1996Article
- Fibroblast-dependent induction of a murine skin lesion with similarity to human common blue nevus.The American journal of pathology · 1996Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Research into the cause and pathophysiological mechanisms underlying expression of psoriatric skin lesions has been hampered by lack of an appropriate animal model for this common and enigmatic cutaneous disease. These studies characterize normal skin, pre-psoriatic skin, and psoriatic plaque skin samples transplanted onto severe combined immunodeficiency mice. In this report we document that 1), normal, prepsoriatic, and psoriatic plaque keratome skin samples can be transplanted onto severe combined immunodeficiency mice reliably with high rates of graft survival (> 85%) and with reproducible changes consistently observed over prolonged periods of engraftment; 2), after transplantation, by clinical assessment and routine light microscopy, normal skin remained essentially normal whereas pre-psoriatic skin became thicker, and psoriatic plaque skin retained its characteristic plaque-type elevation and scale; 3), by using a panel of antibodies and immunohistochemical analysis, the overall phenotype of human cell types (including immunocytes) that persisted in the transplanted skin was remarkably similar to the immunophenotype of pretransplanted skin samples; 4), clearly recognized interface zones between human and murine skin within the epidermal and dermal compartments could be identified by routine microscopy and immunostaining, with focal areas of chimerism; and 5), elevated interleukin 8 cytokine levels were present in transplanted pre-psoriatic and psoriatic plaque skin samples. We conclude that there are many similarities between pre- and post-transplanted human samples of normal and psoriatic skin that are grafted onto severe combined immunodeficiency mice. Thus, we propose that this new animal model is appropriate for additional mechanistic-type studies designed to reveal the underlying genetic/etiological abnormality, as well as better illuminate the pathophysiological basis, for this important skin disease.
Indexed as
Identifiers
7887440PMC1869187W1599590881What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.